UCLA researchers in the Department of Mechanical and Aerospace Engineering have developed a novel massively parallel, single cell electroporation platform (MSEP) that is high throughput, efficient, and maintains cell viability.
Electroporation is clinically used to deliver various extracellular molecules (i.e. drugs, proteins, nucleic acids, nanoparticles, etc.) to cells, tissues, and organisms. However, conventional bulk electroporation techniques require high voltage sources in order to electroporate cells and deliver cargo, resulting in a high percentage of cell death. Microfluidic electroporation devices can provide high delivery efficiency and high cell viability through better-controlled electric fields, but their throughput is orders of magnitude lower than bulk approaches.
Professor Chiou and his research team have developed a novel MSEP that not only overcomes the throughput limitations of microfluidic-based approaches but also uses low voltage sources for high efficiency electroporation with high cell viability post-delivery. This compact, easy-to-use silicon device can deliver cargo in up to 10 million cells/min on a 1 cm2 chip, where calcium dyes, large-sized dextran proteins, and plasmids were successfully delivered to mammalian cells with high efficiency (up to 90%) and high cell viability (up to 90%).
Prototype microfluidic devices have been developed and extensively tested. Cargo delivery (calcium dyes, large-sized dextran proteins, and plasmids) to mammalian cells were successfully demonstrated with high throughput, efficiency, and minimal cell death.
|United States Of America||Published Application||20180066222||03/08/2018||2017-086|
Electroporation, microfluidics, massively parallel single-cell electroporation, MSEP, ultrahigh throughput, drug delivery, cargo delivery, cell delivery, gene delivery